Eva Juengel

2.4k total citations
94 papers, 1.9k citations indexed

About

Eva Juengel is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Eva Juengel has authored 94 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Molecular Biology, 32 papers in Pulmonary and Respiratory Medicine and 19 papers in Oncology. Recurrent topics in Eva Juengel's work include Histone Deacetylase Inhibitors Research (22 papers), Prostate Cancer Treatment and Research (19 papers) and Genomics, phytochemicals, and oxidative stress (11 papers). Eva Juengel is often cited by papers focused on Histone Deacetylase Inhibitors Research (22 papers), Prostate Cancer Treatment and Research (19 papers) and Genomics, phytochemicals, and oxidative stress (11 papers). Eva Juengel collaborates with scholars based in Germany, United Kingdom and United States. Eva Juengel's co-authors include Roman A. Blaheta, Axel Haferkamp, Igor Tsaur, Jasmina Makarević, Jochen Rutz, Georg Bartsch, Karen Nelson, Lukasz Hudak, Igor Tsaur and Sebastian Maxeiner and has published in prestigious journals such as PLoS ONE, International Journal of Molecular Sciences and The Journal of Urology.

In The Last Decade

Eva Juengel

90 papers receiving 1.9k citations

Peers

Eva Juengel

PRM

ONCOL

Addanki P. Kumar United States

Yi‐Hua Jan Taiwan

Aya Naiki‐Ito Japan

Quan Zhang China

Xiaoyu Ji China

Hongfei Wu China

Wanyin Wu China

Chengguang Zhao China

Desong Kong China

Chun‐Yin Huang Taiwan

Addanki P. Kumar United States

Eva Juengel

1.0k ×0.9

274 ×0.6

PRM

436 ×1.2

561 ×1.9

ONCOL

112 ×0.4

Citations per year, relative to Eva Juengel Eva Juengel (= 1×) peers Addanki P. Kumar

Countries citing papers authored by Eva Juengel

Since Specialization

Citations

This map shows the geographic impact of Eva Juengel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Juengel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Juengel more than expected).

Fields of papers citing papers by Eva Juengel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Juengel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Juengel. The network helps show where Eva Juengel may publish in the future.

Co-authorship network of co-authors of Eva Juengel

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Juengel. A scholar is included among the top collaborators of Eva Juengel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Juengel. Eva Juengel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ruckes, Christian, Isabel Wagner, René Mager, et al.. (2025). Complications and oncologic outcome in bladder cancer patients receiving radical cystectomy after intravesical instillation treatment. PLoS ONE. 20(12). e0337644–e0337644.

Xie, Hui, Jochen Rutz, Sebastian Maxeiner, et al.. (2024). Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro. Nutrients. 16(5). 623–623. 3 indexed citations

Markowitsch, Sascha D., Jochen Rutz, Felix K.‐H. Chun, et al.. (2024). Survey of Physicians and Healers Using Amygdalin to Treat Cancer Patients. Nutrients. 16(13). 2068–2068. 2 indexed citations

Markowitsch, Sascha D., Thao Pham, Jochen Rutz, et al.. (2024). Growth of Renal Cancer Cell Lines Is Strongly Inhibited by Synergistic Activity of Low-Dosed Amygdalin and Sulforaphane. Nutrients. 16(21). 3750–3750. 1 indexed citations

Vakhrusheva, Olesya, Holger H.H. Erb, Sascha D. Markowitsch, et al.. (2022). Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer Cells. Frontiers in Oncology. 12. 789284–789284. 20 indexed citations

Thomas, Anita, Luísa Matos do Canto, Cláudia Aparecida Rainho, et al.. (2021). Systemic treatment of penile squamous cell carcinoma—hurdles and hopes of preclinical models and clinical regimens: a narrative review. Translational Andrology and Urology. 10(10). 4085–4098. 7 indexed citations

Erb, Holger H.H., Florian Handle, Igor Tsaur, et al.. (2020). Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. PLoS ONE. 15(8). e0237248–e0237248. 14 indexed citations

Makarević, Jasmina, Jochen Rutz, Eva Juengel, et al.. (2014). Amygdalin Influences Bladder Cancer Cell Adhesion and Invasion In Vitro. PLoS ONE. 9(10). e110244–e110244. 37 indexed citations

Juengel, Eva, Jasmina Makarević, Michael Reiter, et al.. (2014). Resistance to the mTOR Inhibitor Temsirolimus Alters Adhesion and Migration Behavior of Renal Cell Carcinoma Cells through an Integrin α5– and Integrin β3–Dependent Mechanism. Neoplasia. 16(4). 291–300. 15 indexed citations

10.

Mani, Jens, Jasmina Makarević, Eva Juengel, et al.. (2013). I Publish in I Edit? - Do Editorial Board Members of Urologic Journals Preferentially Publish Their Own Scientific Work?. PLoS ONE. 8(12). e83709–e83709. 21 indexed citations

11.

Doberstein, Kai, W. Eberhardt, Michel Mittelbronn, et al.. (2013). MicroRNA-145 Targets the Metalloprotease ADAM17 and Is Suppressed in Renal Cell Carcinoma Patients. Neoplasia. 15(2). 218–IN31. 85 indexed citations

12.

Vallo, Stefan, Jasmina Makarević, Eva Juengel, et al.. (2012). Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. Prostate Cancer and Prostatic Diseases. 15(3). 250–255. 22 indexed citations

13.

Tsaur, Igor, Jasmina Makarević, Lukasz Hudak, et al.. (2011). The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Letters. 313(1). 84–90. 44 indexed citations

14.

Wedel, Steffen, Lukasz Hudak, Jasmina Makarević, et al.. (2011). Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clinical & Experimental Metastasis. 28(5). 479–491. 47 indexed citations

15.

Wedel, Steffen, Lukasz Hudak, Jasmina Makarević, et al.. (2011). Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer. 11(1). 375–375. 24 indexed citations

16.

Vallo, Stefan, Xi Wang, Lukasz Hudak, et al.. (2011). HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anti-Cancer Drugs. 22(10). 1002–1009. 26 indexed citations

17.

Tsaur, Igor, Nicholas Obermüller, Dietger Jonas, et al.. (2010). De novo renal cell carcinoma of native and graft kidneys in renal transplant recipients. British Journal of Urology. 108(2). 229–234. 39 indexed citations

18.

Wedel, Steffen, Lukasz Hudak, Eva Juengel, et al.. (2010). Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. Cancer Letters. 301(1). 17–28. 16 indexed citations

19.

Wedel, Steffen, Eva Juengel, Janice Jones, et al.. (2008). Präklinische Studien zum Einfluss des Tyrosinkinaseinhibitors AEE788 auf die Malignität des Nierenzellkarzinoms. Der Urologe. 47(9). 1175–1181. 2 indexed citations

20.

Jones, Jon, Eva Juengel, Lukasz Hudak, et al.. (2008). The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. Journal of Cellular and Molecular Medicine. 13(8b). 2376–2385. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact